Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

What drives us is the idea that we can design a single drug to treat obesity and simultaneously mitigate the risk of developing a long list of health problems plaguing society,” says Krishna Kumar.

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

The webcast of the live call may be accessed on the Investors section of the iBio website at ir.ibioinc.com/news-events/ir-calendar. A replay of the webcast will be available on the iBio website for ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks. Their effect may not last ...

Bone growth occurs through the proliferation of specialized cells of the cartilage tissue, known as chondrocytes, on either ...

Experimentation has shown that oxytocin, a peptide hormone primarily responsible for parturition, bonding, and lactation, also regulates cognitive behavior in the rodent central nervous system (CNS).

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% meeting criteria for obesity alone, according to the Centers for Disease ...

Crinetics Pharmaceuticals Inc is engaged in the discovery and development of novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers ...